This has recently been reported in a phase I dose escalation trial with propagermaium in patients with breast cancer [31] and a phase 2 trial with anti-MCP-1 (carlumab) in patients with idiopatic pulmonary fibrosis [32]. The gene discussed is CCL2; the disease is pulmonary fibrosis.